Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Falciparum Malaria Vaccines
Studies from Institute of Immunology provide new data on falciparum malaria vaccines
October 22nd, 2008
Research findings, 'Protection against Plasmodium falciparum challenge induced in Aotus monkeys by liver-stage antigen-3-derived long synthetic peptides,' are discussed in a new report. "The vaccine potential of Plasmodium falciparum liver stage antigen-3 (LSA3) was investigated in Aotus monkeys using two long synthetic peptides corresponding respectively to an N-terminal non-repeat peptide (NRP) and repeat 2 (R2) region of the LSA3, adjuvanted by ASO2," scientists in Cali, Colombia report. "Both 100-222 (NRP) and 501-596 repeat peptides induced effector B-and T-cell responses in terms of antigen-driven antibodies and/or specific IFN-gamma secretion. Animals...
Source: Vaccine Weekly (2008-10-22)
|
